| Literature DB >> 19424509 |
Shaista Safder1, Thomas C Chelimsky, Mary Ann O'Riordan, Gisela Chelimsky.
Abstract
BACKGROUND: The pathophysiology of functional abdominal pain (FAP) is unknown. The upright portion of a tilt table test triggers typical symptoms in certain children. AIM: To compare the pathophysiology and treatment response of children with FAP whose gastrointestinal symptoms (GI) were replicated (RGI) by tilt table testing (TTT) to those in whom TTT did not have this effect (NRGI).Entities:
Year: 2009 PMID: 19424509 PMCID: PMC2677655 DOI: 10.1155/2009/868496
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Summary of demographic characteristics and results of autonomic testing in each group.
| Overall | RGI | NRGI |
| |
|---|---|---|---|---|
| Mean age (years) ± SD | 13.4 years ± 3.6 yrs | 12.6 ± 3.3 | 14.1 ± 3.70 | .08 |
| Male gender | 25/76 (32%) | 9 /32 (28%) | 16/44 (36%) | .46 |
| Median duration of symptoms (range in months) | 41.5 ± 24.0 | 29.3 ± 30.9 | 51 ± 45.6 | .04 |
| 24(1-156) | 18(2-120) | 35(1-156) | ||
| Abnormal Valsalva Ratio (no. subjects) | 8/76 (10%) | 1/32 (3%) | 7/44 (15%) | .13 |
| Abnormal Deep Breathing (no. subjects) | 7/76 (9%) | 2/32 (6%) | 5/44 (11%) | .69 |
| Either DB and Valsalva ratio abnormal | 15/76 (20%) | 3/32 (9%) | 12/44 (27%) | .13 |
| Abnormal Axon-Reflex Response | 23/76 (30%) | 10/32 (31%) | 13/44 (29%) | .81 |
| POTS on TTT | 59/76 (77%) | 28/32 (87%) | 31/44 (70%) | .09 |
| Patients on Fludrocortisone | 23/76 (30%) | 15/32 (46%) | 8/44 (18%) | .01 |
| No. Patients with ≥4/5 Treatment response to Fludrocortisone | 13/76 (17%) | 11/32 (34%) | 2/44 (4%) | .09 |
Figure 1Result of Autonomic testing. OI: orthostatic intolerance, DB: Deep breathing, and OH: orthostatic hypotension.
Summary of the most common symptoms in each group.
| Symptom | Overall | RGI | NRGI |
|---|---|---|---|
| Abdominal pain | 43/76 (56%) | 23/32 (71%) | 20/44 (45%) |
| nausea | 8/76 (10%) | 5/32 (15%) | 3/44 (6%) |
| dizziness | 13/76 (17%) | 3/32 (9%) | 10/44 (22%) |
| vomiting | 13/76 (17%) | 4/32 (12%) | 9/44 (20%) |
| syncope | 6/76 (7%) | 2/32 (6%) | 4/44 (9%) |
| fatigue | 2/76 (2%) | 1/32 (3%) | 1/44 (2%) |
| diarrhea | 5/76 (6%) | 1/32 (3%) | 4/44 (9%) |
| headache | 5/76 (6%) | 1/32 (3%) | 4/44 (9%) |
Figure 3Gastrointestinal (GI) Symptom profile of patients who underwent autonomic testing.
Treatment choices in both groups.
| Treatment group | Overall | RGI | NRGI |
|---|---|---|---|
| Volume expansion/ Fludrocortisone | 23/76 (30%) | 15/32 (47%) | 8/44 (18%) |
| Tricyclic antidepressant | 9/76 (12%) | 6/32 (19%) | 3/44 (7%) |
| Beta-blockers | 25/76 (32%) | 10/32 (31%) | 15/44 (34%) |
| Cyproheptadine | 3/76 (4%) | 2/32 (6%) | 1/44 (2%) |
| SSRI's | 18/76 (23%) | 10/32 (31%) | 8/44 (18%) |
| Antiepileptic | 5/76 (6%) | 2/32 (6%) | 3/44 (7%) |
| Proamatine | 9/76 (12%) | 5/32 (16%) | 4/44 (9%) |
| Neurontin | 2/76 (2%) | 1/32 (3%) | 1/44 (2%) |
| Mestinon | 1/76 (1%) | 1/32 (3%) | 0/44 (0%) |
| No Treatment | 17/76 (22%) | 3/32 (9%) | 14/44 (31%) |
Figure 2Fludrocortisone treatment effect.